FIELD: pharmacology.
SUBSTANCE: invention is an oral bio-available non-aqueous liquid composition containing at least 7 wt % of propylene glycol in the total composition weight, a cardiotonic means, or angiotensin-converting enzyme inhibitor, or combination of cardiotonic means and angiotensin-converting enzyme inhibitor. Invention discloses a method for obtaining the composition described above, by mixing at least 7 wt % of propylene glycol by the total composition weight with a cardiotonic means, or angiotensin-converting enzyme inhibitor, or a combination of cardiotonic means with angiotensin-converting enzyme inhibitor.
EFFECT: treatment of heart disease and hypertension.
34 cl, 11 dwg, 17 tbl, 2 ex
